Meeting
2016 ASCO Annual Meeting
De-ESCALaTE: Comparison of early and late toxic events in low-risk HPV positive oropharyngeal carcinoma patients treated with chemoradiotherapy, cetuximab versus cisplatin.
Authors
Hisham Mohamed Mehanna
University of Birmingham, Birmingham, United Kingdom
Hisham Mohamed Mehanna , Christopher C McConkey , Andrew G. J. Hartley , M. Tessa Fulton-Lieuw , Joanne Grumett , Max Robinson , Bernadette Foran , Mehmet Sen , Anthony Kong , Janet Dunn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
ISRCTN33522080
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS6103)
DOI
10.1200/JCO.2016.34.15_suppl.TPS6103
Abstract #
TPS6103
Poster Bd #
424a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.
First Author: Anthony Hee Kong
Poster
2019 ASCO Annual Meeting
Mature results of the LCCC1413 phase II trial of de-intensified chemoradiotherapy for HPV-associated oropharyngeal squamous cell carcinoma.
First Author: Bhishamjit S. Chera
Poster
2018 ASCO Annual Meeting
Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
First Author: Kevin J. Harrington
Poster
2018 ASCO Annual Meeting
Neck dissection rate in node positive human papillomavirus associated oropharyngeal carcinoma following chemoradiotherapy.
First Author: Sandro Porceddu